Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
SRN-001(siRNAgen Therapeutics) in Idiopathic Pulmonary Fibrosis: NCT05984992 Clinical Landscape Report 2026
15 October 2026
NCT05984992 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Pemvidutide in Metabolic Dysfunction Associated Steatohepatitis: NCT05989711 Clinical Landscape Report 2026
15 October 2026
NCT05989711 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
Ubidecarenone in Metabolic Dysfunction Associated Steatohepatitis: NCT05984745 Clinical Landscape Report 2026
15 October 2026
NCT05984745 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
Usnoflast in Amyotrophic Lateral Sclerosis: NCT05981040 Clinical Landscape Report 2026
15 October 2026
NCT05981040 clinical landscape for Amyotrophic Lateral Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Suplatast Tosilate in Idiopathic Pulmonary Fibrosis: NCT05983471 Clinical Landscape Report 2026
15 October 2026
NCT05983471 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Mannitol/Sucralose in Metabolic Dysfunction Associated Steatohepatitis: NCT05983328 Clinical Landscape Report 2026
15 October 2026
NCT05983328 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
Artesunate in Idiopathic Pulmonary Fibrosis: NCT05988463 Clinical Landscape Report 2026
15 October 2026
NCT05988463 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Acetylcysteine in Lung Cancer: NCT05986318 Clinical Landscape Report 2026
15 October 2026
NCT05986318 clinical landscape for Lung Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
FB-418 in Parkinson Disease: NCT05995782 Clinical Landscape Report 2026
15 October 2026
NCT05995782 clinical landscape for Parkinson Disease: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Admilparant in Idiopathic Pulmonary Fibrosis: NCT06003426 Clinical Landscape Report 2026
15 October 2026
NCT06003426 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Semaglutide (Novo Nordisk) in Fibrosis, Liver: NCT06005012 Clinical Landscape Report 2026
15 October 2026
NCT06005012 clinical landscape for Fibrosis, Liver: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Lithium succinate in Amyotrophic Lateral Sclerosis: NCT06008249 Clinical Landscape Report 2026
15 October 2026
NCT06008249 clinical landscape for Amyotrophic Lateral Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.